Clincosm LogoSign in Get a demo

Triple Negative Breast Cancer

Showing NaN - NaN of 21
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

Triple Negative Breast Cancer, PD-L1 Negative Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Paclitaxel,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Negative
  • Sacituzumab Govitecan-hziy
  • +4 more
  • Anchorage, Alaska
  • +231 more
Jan 17, 2023

Triple Negative Breast Cancer, PD-L1 Positive Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Pembrolizumab,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Positive
  • Sacituzumab Govitecan-hziy
  • +5 more
  • Anchorage, Alaska
  • +245 more
Jan 12, 2023

Triple Negative Breast Cancer Trial in Worldwide (Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Concord, California
  • +429 more
Dec 12, 2022

Triple Negative Breast Cancer Trial in United States (ribociclib, Bicalutamide)

Recruiting
  • Triple Negative Breast Cancer
  • Chicago, Illinois
  • +5 more
Oct 31, 2022

NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • Tucson, Arizona
  • +26 more
Aug 1, 2022

Triple Negative Breast Cancer Trial in Canada, United States (Placebo, Atezolizumab)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Mobile, Alabama
  • +216 more
Jul 27, 2022

NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • CART-TnMUC1
  • +2 more
  • Phoenix, Arizona
  • +9 more
Jul 18, 2022

Triple Negative Breast Cancer Trial in Worldwide (biological, device, other)

Recruiting
  • Triple Negative Breast Cancer
  • adagloxad simolenin combined with OBI-821
  • +2 more
  • Harbor City, California
  • +97 more
Jul 5, 2022

Clinical Resistance to Chemotherapy in Triple Negative Breast

Completed
  • Triple Negative Breast Cancer
  • Needle core biopsies
  • Needle core biopsies of metastatic lesion
  • Chicago, Illinois
  • +7 more
May 27, 2022

Breast Cancer, Triple Negative Breast Cancer, Residual Cancer Trial in United States (Atezolizumab, Sacituzumab govitecan)

Recruiting
  • Breast Cancer
  • +3 more
  • San Francisco, California
  • +8 more
May 25, 2022

Triple Negative Breast Cancer Trial in Australia, United States (biological, device, drug)

Recruiting
  • Triple Negative Breast Cancer
  • tavokinogene telseplasmid
  • +3 more
  • Tucson, Arizona
  • +12 more
Apr 18, 2022

Triple Negative Breast Cancer Trial in Worldwide (AL101)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Gilbert, Arizona
  • +28 more
Mar 31, 2022

Triple Negative Breast Cancer Trial in Washington, Chicago, Hackensack (Nivolumab, Capecitabine)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Washington, District of Columbia
  • +3 more
Mar 14, 2022

Triple Negative Breast Cancer Trial in Chicago (Carboplatin, Paclitaxel, Doxorubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Chicago, Illinois
    University of Illinois
Jan 28, 2022

Advanced Cancer, Ovarian Cancer, Breast Cancer Trial in United States (COM701, COM701 with Opdivo (Nivolumab).)

Recruiting
  • Advanced Cancer
  • +9 more
  • COM701
  • COM701 with Opdivo (Nivolumab).
  • Los Angeles, California
  • +10 more
Jan 25, 2022

Triple Negative Breast Cancer Trial in Worldwide (Cyclophosphamide, Placebo, Doxorubicin)

Completed
  • Triple Negative Breast Cancer
  • Scottsdale, Arizona
  • +157 more
Jan 15, 2021

Triple Negative Breast Cancer Trial in Worldwide (Tivozanib Hydrochloride, paclitaxel, Placebo)

Terminated
Has Results
  • Triple Negative Breast Cancer
  • Tivozanib Hydrochloride
  • +2 more
  • Birmingham, Alabama
  • +53 more
Oct 5, 2020

Solid Tumor, Triple Negative Breast Cancer Trial in United States (RX-5902)

Terminated
  • Solid Tumor
  • Triple Negative Breast Cancer
  • Tucson, Arizona
  • +7 more
Jan 3, 2020

Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer Trial in United States (Abraxane alone, Abraxane +

Completed
Has Results
  • Breast Cancer
  • +3 more
  • Abraxane alone
  • Abraxane + Tigatuzumab
  • Birmingham, Alabama
  • +9 more
Oct 24, 2017

Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast

Terminated
Has Results
  • Estrogen Receptor Negative Breast Cancer
  • +5 more
  • Birmingham, Alabama
  • +15 more
May 22, 2017